Drugs / RC18
RC18
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04235933 | Sep → Dec 2019 | — | RemeGen Co., Ltd. | Completed | No outcome recorded |
| Phase 25 trials · 1 met primary | ||||||
| Phase 2 | NCT04625153 | May 2021 → Apr 2026 | relapsing-remitting multiple sclerosis | RemeGen Co., Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT04291781 | Apr 2020 → May 2021 | IgA glomerulonephritis | RemeGen Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04078386 | Nov 2019 → Jun 2021 | Sjogren syndrome | RemeGen Co., Ltd. | Completed | Mixed |
| Phase 2 | NCT02885610 | Dec 2015 → Jun 2019 | systemic lupus erythematosus | RemeGen Co., Ltd. | Completed | Met primary |
| Phase 2 | NCT02882087 | Oct 2015 → Feb 2019 | rheumatoid arthritis | RemeGen Co., Ltd. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 32 trials | ||||||
| Phase 3 | NCT03330418 | Jan 2018 → Apr 2026 | neuromyelitis optica | RemeGen Co., Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT03016013 | Mar 2017 → Nov 2022 | rheumatoid arthritis | RemeGen Co., Ltd. | Completed | No outcome recorded |
Press releases naming this drug 20 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RC18 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04078386 ↗ |
| Known as | Tai Ai | “Tai Ai(RC18) 80mg” NCT04235933 ↗ |
| Known as | telitacicept | “Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial.” PMID 38129117 ↗ Mar 2024 |
| Action | Inhibit | “a novel fusion protein that neutralises signals of B lymphocyte stimulator and a proliferation-inducing ligand” PMID 38129117 ↗ Mar 2024 |
| Modality | Protein / enzyme biologic | “recombinant human B lymphocyte stimulating factor receptor-antibody fusion protein” NCT02882087 ↗ |
| Route | Subcutaneous | “Patients received the test group RC18 160mg weekly administered subcutaneously for 24 times.” NCT02882087 ↗ |